ABEO Stock Summary and Trading Ideas (Abeona Therapeutics | NASDAQ:ABEO)

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Abeona Therapeutics trades on the NASDAQ stock market under the symbol ABEO.

As of March 27, 2026, ABEO stock price declined to $4.29 with 1,121,844 million shares trading.

ABEO has a beta of 1.34, meaning it tends to be more sensitive to market movements. ABEO has a correlation of 0.16 to the broad based SPY ETF.

ABEO has a market cap of $244.74 million. This is considered a Small Cap stock.

Last quarter Abeona Therapeutics reported $5 million in Revenue and -$.34 earnings per share. This beat revenue expectation by $503,400 and exceeded earnings estimates by $.02.

In the last 3 years, ABEO traded as high as $9.01 and as low as $2.65.

The top ETF exchange traded funds that ABEO belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

ABEO has underperformed the market in the last year with a price return of -14.9% while the SPY ETF gained +13.1%. ABEO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.3% and -9.9%, respectively, while the SPY returned -7.9% and -4.0%, respectively.

ABEO support price is $4.18 and resistance is $4.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABEO shares will trade within this expected range on the day.